<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01101360</url>
  </required_header>
  <id_info>
    <org_study_id>DC75761</org_study_id>
    <nct_id>NCT01101360</nct_id>
  </id_info>
  <brief_title>Port Wine Stains Treatment Matrix RF Study</brief_title>
  <official_title>Evaluation of Fractional Radiofrequency (Matrix RF) Stand Alone and Combined With PDL Treatment on Port Wine Stains</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Syneron Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Syneron Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of the Matrix RF for Port
      Wine Stains based on clinical and histological analyses.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to complete healing</measure>
    <time_frame>Up to 30 weeks</time_frame>
    <description>Assess safety of the Matrix RF treatment for port wine stains</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events recording and monitoring</measure>
    <time_frame>Up to 40 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clearance of port wine stain</measure>
    <time_frame>Up to 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lightening of the port wine stain</measure>
    <time_frame>Up to 40 weeks</time_frame>
    <description>Evaluation of lightening of the port wine stain will be made with reflectance spectrophotometer at all treatments and at 6 and 12 weeks following the last treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of port wine stain</measure>
    <time_frame>Up to 30 weeks</time_frame>
    <description>Assessment to be done by the subject via subject questionnaire during these visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in blood vessel concentration</measure>
    <time_frame>Up to 40 weeks</time_frame>
    <description>Biopsies taken from consenting subjects at one of the time points will be analyzed</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Port Wine Stains</condition>
  <arm_group>
    <arm_group_label>Matrix RF followed by Pulse Dye Laser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Matrix RF</intervention_name>
    <description>Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)</description>
    <arm_group_label>Matrix RF followed by Pulse Dye Laser</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Matrix RF followed by Pulse Dye Laser</intervention_name>
    <description>Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)</description>
    <arm_group_label>Matrix RF followed by Pulse Dye Laser</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pulse Dye Laser followed by Matrix RF</intervention_name>
    <description>Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)</description>
    <arm_group_label>Matrix RF followed by Pulse Dye Laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent agreement signed by the subject.

          -  Healthy males or females older than 18 to 65 years of age.

          -  Having a low to mid depth Port Wine Stain of at least 5 cm2.

          -  Willingness to follow the treatment and follow-up schedule and the post-treatment
             care.

          -  For female candidates - post-menopausal or surgically sterilized, or using a medically
             acceptable form of birth control at least 3 months prior to enrollment and during the
             entire course of the study (i.e., oral contraceptives, IUD, contraceptive implant,
             barrier methods with spermicide, or abstinence).

        Exclusion Criteria:

          -  PWS on lower legs or hands.

          -  Pregnant and/or breastfeeding.

          -  Having any active electrical implant anywhere in the body, such as a pacemaker or an
             internal defibrillator.

          -  Having a permanent implant in the treated area, such as an injected chemical substance
             in the face (if treated).

          -  Having a history of diseases stimulated by heat, such as recurrent Herpes Simplex in
             the treated area, unless treatment is conducted following a prophylactic regimen.

          -  Use of non-steroidal anti-inflammatory drugs (NSAIDS, e.g., ibuprofen-containing
             agents) one week before and after each treatment session.

          -  Use of retinoids, antioxidants or medical grade of skin nourishing supplements within
             2 months of treatment or during the study.

          -  Having received a facial dermabrasion or chemical peel treatment within 3 months of
             treatment or during the study (if face is treated).

          -  Having received treatment with light, RF or other devices in the treated area within 6
             months of treatment or during the study.

          -  Having received Botox/collagen/fat injections or other methods of augmentation with
             injected or implanted material in the treated area within 9 months of treatment or
             during the study (if face is treated).

          -  Having undergone a resurfacing procedure, face lift or eyelid surgery within a year of
             treatment or during the study (if face is treated).

          -  Having undergone any other surgery in the treated area within 6 months of treatment
             (or more if skin has not healed completely) or during the study.

          -  History of keloid scarring or of abnormal wound healing.

          -  Suffering from current or history of significant skin conditions in the treated area
             or inflammatory skin conditions, including, but not limited to: active acne, excessive
             skin dryness, psoriasis, eczema, rash, rosacea (particularly severe open wound stage),
             varicella scars, open lacerations or abrasions and active cold sores or herpes sores
             prior to treatment (duration of resolution as per the Investigator's discretion) or
             during the treatment course.

          -  History of immunosuppression/immune deficiency disorders (including HIV infection or
             AIDS) or currently using immunosuppressive medications.

          -  History of epidermal or dermal disorders (particularly if involving collagen or
             microvascularity).

          -  History of pigmentary disorders, particularly tendency for hyper- or
             hypo-pigmentation.

          -  Suffering from hormonal imbalance, as per the Investigator's discretion.

          -  Having a known anticoagulative or thromboembolic condition or taking anticoagulation
             medications one week prior to and during the treatment course (to allow inclusion,
             temporary cessation of use as per the subject's physician discretion).

          -  Having or undergoing any form of treatment for active cancer, or having a history of
             skin cancer or any other cancer in the areas to be treated, including actinic
             keratosis, presence of malignant or pre-malignant pigmented lesions.

          -  Suffering from significant concurrent illness, such as cardiac disorders, diabetes
             (type I or II), or pertinent neurological disorders.

          -  Tattoo or permanent make-up in the treated area.

          -  Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning
             during the study.

          -  Participation in a study of another device or drug within three month prior to
             enrollment or during the study.

          -  As per the Investigator's discretion, any physical or mental condition which might
             make it unsafe for the subject to participate in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Laser and Skin Surgery Center of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2010</study_first_submitted>
  <study_first_submitted_qc>April 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2010</study_first_posted>
  <last_update_submitted>November 30, 2014</last_update_submitted>
  <last_update_submitted_qc>November 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>port wine stains</keyword>
  <keyword>radiofrequency</keyword>
  <keyword>Pulse Dye Laser</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Port-Wine Stain</mesh_term>
    <mesh_term>Hemangioma, Capillary</mesh_term>
    <mesh_term>Vascular Malformations</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

